Welcome to our dedicated page for Bausch Health Companies news (Ticker: BHC), a resource for investors and traders seeking the latest updates and insights on Bausch Health Companies stock.
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global leader in the pharmaceutical, medical device, and over-the-counter product industries, primarily focusing on the therapeutic areas of eye health, gastroenterology, and dermatology. The company is dedicated to advancing global health through innovation and efficient healthcare solutions.
With approximately 22,000 employees worldwide, Bausch Health operates in around 100 countries. The company's core business is organized into five segments: Salix Pharmaceuticals, International, Solta Medical, Diversified Products, and Bausch + Lomb, with the Bausch + Lomb segment generating the highest revenue. Bausch Health consistently delivers on its commitments to quality health care outcomes and customer focus.
Recent achievements include significant progress in the development of Amiselimod, a promising new treatment for ulcerative colitis, and the expansion of public drug plan listings for UCERIS® (budesonide) aerosol foam in multiple Canadian provinces. Additionally, Bausch Health has launched an awareness campaign for XIFAXAN®, an FDA-approved medication for reducing the risk of overt hepatic encephalopathy recurrence.
Financially, Bausch Health reported strong performance in the first quarter of 2024, with revenues of $2.15 billion, marking a 11% increase compared to the prior year. The company continues to strengthen its balance sheet while advancing its R&D pipeline and executing commercial strategies for global growth.
Bausch Health remains focused on protecting its intellectual property, as evidenced by recent litigation efforts to defend the XIFAXAN® franchise. The company is also committed to fostering partnerships and collaborations to enhance its product offerings and reach.
For more information, visit www.bauschhealth.com.
Bausch Health and Salix Pharmaceuticals launched digital initiatives for Constipation Awareness Month, focusing on opioid-induced constipation (OIC), irritable bowel syndrome with constipation (IBS-C), and chronic idiopathic constipation (CIC). Their campaign aims to enhance patient education and awareness through platforms like TikTok and revamped websites, including UnderstandingOIC.com. Highlights include partnerships with healthcare influencers to discuss symptoms and treatment options, addressing the fact that 40-80% of chronic pain patients experience OIC.
Bausch + Lomb, part of Bausch Health (NYSE/TSX: BHC), announced that its exclusive recycling programs, ONE by ONE and Biotrue®, have successfully recycled over 41 million units (248,516 pounds) of used contact lens and eye care materials. The Biotrue® program is the first of its kind in the U.S., having collected more than 65,000 units since launch. These initiatives, in partnership with TerraCycle, promote sustainability by addressing waste that typically ends up in landfills. The company aims to expand these efforts to further reduce environmental impact.
Kroll Bond Rating Agency (KBRA) has released its Third-Quarter 2021 U.S. Bank Compendium, providing insights into the U.S. banking sector's performance and outlook for 2022. The report reviews 3Q21 results for U.S. banks under KBRA ratings, focusing on key credit metrics and ratios. Additionally, it highlights the top 10 banks with the lowest cost deposits and analyzes changes in return on assets and nonperforming asset ratios. The compendium also includes a detailed supplement of 187 rated bank debt issues. Amalgamated Financial Corp. (NASDAQ: AMAL) holds a BBB rating with a Stable Outlook.
Bausch Health Companies Inc. (NYSE/TSX: BHC) announced that its gastroenterology business, Salix Pharmaceuticals, will present new data on rifaximin at The Liver Meeting™ 2021, taking place virtually from Nov. 12-15, 2021. Two abstracts will be available to registered attendees, highlighting studies on rifaximin's role in reducing hospitalization and mortality in patients with hepatic encephalopathy, as well as its use in emergency department services for cirrhosis patients. XIFAXAN® (rifaximin) is indicated for reducing hepatic encephalopathy recurrence and treating IBS-D.
Bausch Health Companies (NYSE/TSX: BHC) announced its participation in two significant investor conferences. The leadership team, including Joseph C. Papa and Sam Eldessouky, will present at the Credit Suisse 30th Annual Healthcare Conference on Nov. 10, 2021, at 10:30 a.m. ET, and at the Evercore ISI HealthCONx Conference on Dec. 1, 2021, at 1:00 p.m. ET. A live webcast will be available on the company’s Investor Relations page.
Bausch Health Companies reported third-quarter 2021 revenues of $2.111 billion, down 1% from $2.138 billion year-over-year. GAAP net income surged to $188 million, compared to $71 million in Q3 2020. The company plans to launch IPOs for Solta Medical in December 2021 or January 2022, followed by Bausch + Lomb about 30 days later. Bausch Health reaffirmed its full-year 2021 guidance with revenue expectations of $8.40 – $8.60 billion and Adjusted EBITDA between $3.35 – $3.50 billion.
Bausch Health Companies (NYSE/TSX: BHC) will present seven scientific posters and data from its ARMOR surveillance study at the American Academy of Optometry and American Academy of Ophthalmology meetings held in November 2021. Key presentations include analyses on the newly FDA-approved XIPERE™ for macular edema and the Bausch + Lomb INFUSE® Multifocal contact lenses. The company's commitment to educating eye care professionals through promotional events highlights its dedication to addressing patient needs.
Bausch Health has launched the Biotrue® Eye Care Recycling program, the first of its kind in the United States, allowing consumers to recycle eye drop single dose units, lens cases, and Biotrue® multi-dose bottles. This initiative, in collaboration with TerraCycle, aims to reduce environmental waste from these products. Participants can sign up for the program, collect eligible items, and mail them to TerraCycle for proper recycling. The program supports Bausch's ongoing commitment to sustainability in eye care packaging.
Bausch Health and its subsidiary Salix Pharmaceuticals released the Liver Health Annual Trends Report, highlighting critical gaps in chronic liver disease (CLD) care in the U.S. The report surveyed 100 healthcare providers, revealing that 38% are unaware of CLD management guidelines. An alarming 51% do not follow current American Association for the Study of Liver Diseases (AASLD) guidelines. CLD affects approximately 4.5 million Americans, with increasing cases of nonalcoholic fatty liver disease noted. The report emphasizes the urgent need for improved education and adherence to treatment standards.
Bausch Health Companies Inc. (BHC) announced the presentation of seven research findings related to its products XIFAXAN®, TRULANCE®, and RELISTOR® at the American College of Gastroenterology 2021 Annual Scientific Meeting in Las Vegas, from October 22-27, 2021. The new clinical data aims to improve patient care for gastrointestinal disorders. Salix Pharmaceuticals, a subsidiary, leads this initiative, reflecting its commitment to advancing gastrointestinal health.
FAQ
What is the current stock price of Bausch Health Companies (BHC)?
What is the market cap of Bausch Health Companies (BHC)?
What are the primary areas of focus for Bausch Health?
How many employees does Bausch Health have?
In how many countries does Bausch Health operate?
What is Bausch Health's largest revenue-generating segment?
What recent product development has Bausch Health achieved?
What financial performance did Bausch Health report for Q1 2024?
How is Bausch Health protecting its intellectual property?
Where can I find more information about Bausch Health?
What recent public drug plan listings has Bausch Health achieved in Canada?
Who is the brand ambassador for the XIFAXAN® awareness campaign?
